Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK+ disease. Several randomized trials have proven tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Spitaleri, Gianluca, Trillo Aliaga, Pamela, Attili, Ilaria, Del Signore, Ester, Corvaja, Carla, Corti, Chiara, Crimini, Edoardo, Passaro, Antonio, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217667/
https://www.ncbi.nlm.nih.gov/pubmed/37232842
http://dx.doi.org/10.3390/curroncol30050384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217667/
https://www.ncbi.nlm.nih.gov/pubmed/37232842
http://dx.doi.org/10.3390/curroncol30050384

Ejemplares similares